Erythema multiforme induced by sorafenib

Clinical and Experimental Dermatology

Volumn 34, Issue 7, 2009, Pages

  Feltes, R A ^a   Feito Rodriguez M ^a   Gonzalez Beato M J ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; NEVAXAR; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ADULT; ANEMIA; ARTIFICIAL EMBOLISM; CASE REPORT; DRUG ERUPTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FEMALE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; LETTER; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN BIOPSY; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DRUG ERUPTIONS; ERYTHEMA MULTIFORME; FEMALE; HUMANS; KIDNEY NEOPLASMS; PYRIDINES;

EID: 70349519356     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03320.x     Document Type: Letter

References (5)

1. Bayer Pharmaceuticals, West Haven, CT. Nexavar (sorafenib) tablets oral: product information. Available at : http://www.univgraph.com/bayer/inserts/ NexavarNAV-PI.pdf. accessed 12 November 2008.
2. McKeage K, Wagstaff AJ. Sorafenib: in advanced renal cancer. Drugs 2007 67 : 475 483.
3. Autier J, Escudier B, Weschsler J et al. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor. Arch Dermatol 2008 144 : 886 892.
4. Strumberg D, Awada A, Hirte H et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumor: Is rash associated with treatment outcome? Eur J Cancer 2006 42 : 548 556.
5. MacGregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenib-induced erythema multiforme. J Am Acad Dermatol 2006 56 : 527 528.